Capricor Therapeutics Inc (CAPR) is a publicly traded Healthcare sector company. As of May 21, 2026, CAPR trades at $30.24 with a market cap of $1.62B and a P/E ratio of -24.46. CAPR moved +7.82% today. Year to date, CAPR is +16.93%; over the trailing twelve months it is +163.49%. Its 52-week range spans $4.30 to $40.37. Analyst consensus is strong buy with an average price target of $54.50. Rallies surfaces CAPR's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Hedge funds tracked by Rallies that own CAPR include Farallon Capital. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for Capricor Therapeutics Inc.
| Metric | Value |
|---|---|
| Price | $30.24 |
| Market Cap | $1.62B |
| P/E Ratio | -24.46 |
| EPS | $-1.15 |
| Dividend Yield | 0.00% |
| 52-Week High | $40.37 |
| 52-Week Low | $4.30 |
| Volume | 12 |
| Avg Volume | 0 |
| Revenue (TTM) | $22.27M |
| Net Income | $-40.47M |
| Gross Margin | 0.00% |
8 analysts cover CAPR: 0 strong buy, 8 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $54.50.